查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1957267

肛門裂傷治療市場－全球產業規模、佔有率、趨勢、機會和預測：按治療類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Anal Fissure Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肛門裂傷治療市場預計將從 2025 年的 20.3 億美元成長到 2031 年的 30.3 億美元，複合年成長率達到 6.91%。

此領域涵蓋多種旨在治療肛裂的藥物和外科手術，主要療法包括局部硝酸鹽類藥物、鈣離子通道阻斷劑和括約肌切開術。市場成長的主要促進因素是久坐不動的生活方式和慢性便秘導致肛管承受的壓力增加。世界胃腸病學會聯盟（WGO）在2024年發布的報告也印證了這一趨勢，報告指出功能性便秘是全球最常見的胃腸道功能性疾病，影響著11.7%的人口，並且是肛門裂傷的主要前驅症狀之一。

市場概覽
預測期 2027-2031
市場規模：2025年 20.3億美元
市場規模：2031年 30.3億美元
複合年成長率：2026-2031年 6.91%
成長最快的細分市場 鈣離子通道阻斷劑
最大的市場 北美洲

儘管市場具有成長潛力，但現有治療方法的安全性問題仍構成重大障礙。手術治療方法通常伴隨大便失禁的風險，而藥物治療則常引起嚴重的頭痛，導致患者和醫護人員都對此有所抵觸。這些副作用往往會導致治療延誤，因為人們更傾向於採取保守的生活方式調整。因此，如何在確保療效的同時避免嚴重副作用，是市場擴張的主要障礙。

市場促進因素

胃腸道疾病和慢性便秘發病率的上升正顯著影響全球肛門裂傷治療市場，導致需要接受治療的患者數量持續成長。諸如大便乾結和排便時長期用力等症狀會對肛門皮膚造成機械性損傷，直接導致肛裂。根據MedCentral於2024年1月發布的報告，基於羅馬IV標準，6%的美國成年人患有慢性特發性便秘。此外，自體免疫疾病的流行也使肛門直腸健康問題更加複雜。根據克隆氏症和結腸炎基金會於2024年5月發布的報告，全球有超過1,000萬人患有發炎性腸道疾病，而這群患者尤其容易出現複雜性肛裂，需要接受專門治療。

另一個重要的促進因素是對非手術治療方法和先進局部用藥日益成長的需求。患者和醫生都在努力避免傳統括約肌切開術帶來的尿失禁風險，而製藥業正在開發兼具高效性和安全性的治療方法。這將提高患者的治療依從性，並有助於早期療育。根據Calkin Media於2024年12月報道，FDA核准Acrux公司的0.4%硝酸甘油軟膏作為學名藥上市，就是此一趨勢的例證。該產品的目標市場規模預計每年超過2,300萬美元。此類核准凸顯了製藥業向非侵入性治療方法方式提供了介於生活方式管理和手術介入之間的折衷方案。

市場挑戰

全球肛門裂傷治療市場擴張的主要障礙在於現有高效能治療方法的安全性問題。由於嚴重不利事件的風險，患者和臨床醫生往往對藥物或手術干預猶豫不決，從而阻礙了市場成長。這種謹慎的態度導致人們長期依賴保守的生活方式管理策略，而這些策略無法帶來實際收益，最終導致每年手術量和藥物處方量大幅下降。

由於手術可能造成永久性功能障礙，因此通常被視為最後的選擇，人們對手術介入的擔憂尤其突出。根據歐洲大腸直腸病學會 (ESCRP) 2024 年的數據，側位內括約肌切開術後大便失禁的發生率估計介於 3% 至 15% 之間。這些數據加劇了人們對患者長期生活品質的擔憂，並成為侵入性治療的一大障礙。因此，市場成長停滯不前，因為對這些潛在的嚴重副作用的擔憂超過了對快速緩解症狀的渴望。

市場趨勢

微創雷射療法正迅速改變外科領域，成為一種無需手術即可保留括約肌的治療方法，可取代傳統的橫向內側括約肌手術。這些技術利用二氧化碳雷射和二極體雷射，無需大規模切口即可有效放鬆內括約肌並去除纖維化組織，從而避免了影響腸道功能的大切口，緩解了長期以來人們對手術安全性的擔憂。與傳統手術刀手術相比，此方法術後疼痛更輕、恢復時間更短，因此越來越受歡迎。 2024年10月發表在《雷射醫學科學期刊》（Journal of Lasers in Medical Sciences）上的一項研究報告稱，在38例接受高功率二極體雷射治療的患者中，平均疼痛評分從術前的4.1分降至術後60天的0.1分，輕微併發症發生率僅為7.9%。

同時，肉毒桿菌注射合併肛裂切除術正逐漸成為保守治療失敗和侵入性手術之間理想的過渡方案。此方法之所以獲得認可，是因為它透過誘導暫時性括約肌麻痺來促進癒合，而無需永久性肌肉切斷，從而避免了永久性肌肉切斷帶來的高失禁風險。這種策略兼顧了臨床療效和腸道功能的保留，並被病人和醫護人員所接受。根據發表於2024年9月《澳新外科日誌》（ANZ Journal of Surgery）的一項包含978例病例的系統評價，該通訊協定的綜合治癒率達到81%，暫時性失禁發生率僅為1%，使其成為傳統手術的一種安全替代方案。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：肛門裂傷治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（瀉藥、局部硝酸鹽、鈣離子通道阻斷劑、大便軟化劑、手術等）
    • 給藥途徑（口服、局部、其他）
    • 通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肛門裂傷治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肛門裂傷治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肛門裂傷治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲肛門裂傷治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲肛門裂傷治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球肛門裂傷治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • RDD Pharma Ltd.
  • Cipla Limited
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Troikaa Pharmaceuticals Ltd.
  • Kyowa Kirin Co., Ltd.
  • Lupin Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24367

The Global Anal Fissure Treatment Market is projected to expand from USD 2.03 Billion in 2025 to USD 3.03 Billion by 2031, achieving a compound annual growth rate of 6.91%. This sector encompasses a range of pharmacological agents and surgical procedures aimed at healing tears in the anoderm, with primary offerings including topical nitrates, calcium channel blockers, and sphincterotomy interventions. Market growth is largely fueled by the increasing prevalence of sedentary lifestyles and chronic constipation, which place significant strain on the anal canal. Highlighting this trend, the World Gastroenterology Organisation reported in 2024 that functional constipation acts as the most widespread functional gastrointestinal disorder globally, affecting 11.7% of the population and serving as a major precursor to anal fissures.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.03 Billion
Market Size 2031USD 3.03 Billion
CAGR 2026-20316.91%
Fastest Growing SegmentCalcium Channel Blockers
Largest MarketNorth America

Despite this growth potential, the market encounters substantial obstacles related to the safety profiles of available treatments. Surgical options are often associated with risks of fecal incontinence, while pharmacological therapies frequently induce severe headaches, leading to reluctance among both patients and healthcare providers. These adverse effects often result in delayed medical treatment as individuals prefer conservative lifestyle adjustments instead. Consequently, the challenge of achieving high therapeutic efficacy without causing significant side effects acts as a primary barrier to broader market development.

Market Driver

The rising incidence of gastrointestinal disorders and chronic constipation significantly influences the Global Anal Fissure Treatment Market by ensuring a steady stream of patients needing medical attention. Conditions characterized by hard stools and chronic straining inflict mechanical damage on the anoderm, directly leading to fissure development. A January 2024 report by MedCentral noted that 6% of adults in the United States suffer from Chronic Idiopathic Constipation based on Rome IV criteria. Additionally, the prevalence of autoimmune diseases further complicates anorectal health; the Crohn's & Colitis Foundation's May 2024 report indicates that over 10 million individuals globally live with inflammatory bowel disease, a group particularly prone to complex fissures that necessitate specialized care.

Another pivotal driver is the growing demand for non-surgical alternatives and advanced topical medications, as patients and doctors strive to avoid the incontinence risks linked to traditional sphincterotomy. The pharmaceutical industry is increasingly developing treatments that balance high effectiveness with enhanced safety to improve patient adherence and facilitate earlier intervention. This trend is highlighted by Acrux Ltd's receipt of FDA approval for a generic Nitroglycerin Ointment 0.4%, as reported by Kalkine Media in December 2024, targeting a market segment worth over USD 23 million annually. Such approvals underscore the industry's strategic shift toward non-invasive solutions that offer a middle ground between lifestyle management and surgical necessity.

Market Challenge

The primary impediment to the expansion of the Global Anal Fissure Treatment Market is the problematic safety profile of existing high-efficacy treatments. Growth is stifled because patients and clinicians often hesitate to pursue medical or surgical interventions due to the significant risk of adverse outcomes. This caution leads to an extended reliance on conservative lifestyle management strategies that generate no revenue, effectively lowering the annual volume of surgical procedures and pharmacological prescriptions.

Fear regarding surgical interventions is especially pronounced, as these procedures are frequently seen as a last resort because of the risk of permanent functional damage. Data from the European Society of Coloproctology in 2024 estimates that lateral internal sphincterotomy carries a postoperative fecal incontinence rate between 3% and 15%. These statistics reinforce patient concerns about long-term quality of life, acting as a major deterrent to invasive therapies. As a result, market growth stagnates because the anxiety over these potentially debilitating side effects outweighs the desire for rapid symptomatic relief.

Market Trends

Minimally invasive laser therapies are rapidly reshaping the surgical sector by providing a sphincter-sparing substitute for traditional lateral internal sphincterotomy. Utilizing CO2 or diode lasers, these techniques effectively relax the internal anal sphincter and ablate fibrotic tissue without the extensive cutting that endangers continence, thereby mitigating long-standing safety concerns. The popularity of this approach is increasing due to reduced postoperative pain and quicker recovery times relative to scalpel-based methods. A study published in the Journal of Lasers in Medical Sciences in October 2024 reported that among 38 patients receiving high-power diode laser therapy, mean pain scores dropped from 4.1 pre-operatively to 0.1 by day 60, with minor complications occurring in only 7.9% of cases.

Simultaneously, the combination of Botulinum Toxin injections with fissurectomy is becoming a favored intermediary step between failed conservative treatments and invasive surgery. This method is gaining ground because it induces temporary sphincter paralysis to facilitate healing without the permanent muscle division that carries high incontinence risks. This strategy offers a balance of clinical success and bowel function preservation that appeals to both patients and providers. According to a September 2024 systematic review in the ANZ Journal of Surgery involving 978 patients, this protocol demonstrated an 81% pooled healing rate while keeping transient incontinence rates at a negligible 1%, establishing it as a safe alternative to conventional surgery.

Key Market Players

  • AbbVie Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • RDD Pharma Ltd.
  • Cipla Limited
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Troikaa Pharmaceuticals Ltd.
  • Kyowa Kirin Co., Ltd.
  • Lupin Limited

Report Scope

In this report, the Global Anal Fissure Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anal Fissure Treatment Market, By Treatment Type

  • Laxatives
  • Topical Nitrates
  • Calcium Channel Blockers
  • Stool Softeners
  • Surgery
  • Others

Anal Fissure Treatment Market, By Route of Administration

  • Oral
  • Topical
  • Others

Anal Fissure Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Anal Fissure Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anal Fissure Treatment Market.

Available Customizations:

Global Anal Fissure Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anal Fissure Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Laxatives, Topical Nitrates, Calcium Channel Blockers, Stool Softeners, Surgery, Others)
    • 5.2.2. By Route of Administration (Oral, Topical, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Anal Fissure Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anal Fissure Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Anal Fissure Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Anal Fissure Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Anal Fissure Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anal Fissure Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Anal Fissure Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Anal Fissure Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Anal Fissure Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Anal Fissure Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Anal Fissure Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anal Fissure Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Anal Fissure Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Anal Fissure Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Anal Fissure Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Anal Fissure Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Anal Fissure Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anal Fissure Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Anal Fissure Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Anal Fissure Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Anal Fissure Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anal Fissure Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Anal Fissure Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Anal Fissure Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anal Fissure Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Teva Pharmaceutical Industries Ltd.
  • 15.4. RDD Pharma Ltd.
  • 15.5. Cipla Limited
  • 15.6. Sanofi SA
  • 15.7. Boehringer Ingelheim International GmbH
  • 15.8. Troikaa Pharmaceuticals Ltd.
  • 15.9. Kyowa Kirin Co., Ltd.
  • 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer